Targeting cyclin D-CDK4/6 sensitizes immune-refractory cancer by blocking the SCP3–NANOG axis

Se Jin Oh, Hanbyoul Cho, Suhyun Kim, Kyung Hee Noh, Kwon Ho Song, Hyo Jung Lee, Seon Rang Woo, Suyeon Kim, Chel Hun Choi, Joon Yong Chung, Stephen M. Hewitt, Jae Hoon Kim, Seungki Baek, Kyung-Mi Lee, Cassian Yee, Hae Chul Park, Tae Woo Kim

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Immunoediting caused by antitumor immunity drives tumor cells to acquire refractory phenotypes. We demonstrated previously that tumor antigen–specific T cells edit these cells such that they become resistant to CTL killing and enrich NANOGhigh cancer stem cell-like cells. In this study, we show that synaptonemal complex protein 3 (SCP3), a member of the Cor1 family, is overexpressed in immunoedited cells and upregulates NANOG by hyperactivating the cyclin D1–CDK4/6 axis. The SCP3–cyclin D1–CDK4/6 axis was preserved across various types of human cancer and correlated negatively with progression-free survival of cervical cancer patients. Targeting CDK4/6 with the inhibitor palbociclib reversed multiaggressive phenotypes of SCP3high immunoedited tumor cells and led to long-term control of the disease. Collectively, our findings establish a firm molecular link of multiaggressiveness among SCP3, NANOG, cyclin D1, and CDK4/6 and identify CDK4/6 inhibitors as actionable drugs for controlling SCP3high immune-refractory cancer. Significance: These findings reveal cyclin D1-CDK4/6 inhibition as an effective strategy for controlling SCP3high immune-refractroy cancer.

Original languageEnglish
Pages (from-to)2638-2653
Number of pages16
JournalCancer Research
Volume78
Issue number10
DOIs
Publication statusPublished - 2018 May 15

Fingerprint

Cyclin D
Synaptonemal Complex
Neoplasms
Cyclin D1
Phenotype
Cyclins
Neoplastic Stem Cells
Uterine Cervical Neoplasms
Disease-Free Survival
Immunity
Proteins
Up-Regulation
T-Lymphocytes
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Targeting cyclin D-CDK4/6 sensitizes immune-refractory cancer by blocking the SCP3–NANOG axis. / Oh, Se Jin; Cho, Hanbyoul; Kim, Suhyun; Noh, Kyung Hee; Song, Kwon Ho; Lee, Hyo Jung; Woo, Seon Rang; Kim, Suyeon; Choi, Chel Hun; Chung, Joon Yong; Hewitt, Stephen M.; Kim, Jae Hoon; Baek, Seungki; Lee, Kyung-Mi; Yee, Cassian; Park, Hae Chul; Kim, Tae Woo.

In: Cancer Research, Vol. 78, No. 10, 15.05.2018, p. 2638-2653.

Research output: Contribution to journalArticle

Oh, SJ, Cho, H, Kim, S, Noh, KH, Song, KH, Lee, HJ, Woo, SR, Kim, S, Choi, CH, Chung, JY, Hewitt, SM, Kim, JH, Baek, S, Lee, K-M, Yee, C, Park, HC & Kim, TW 2018, 'Targeting cyclin D-CDK4/6 sensitizes immune-refractory cancer by blocking the SCP3–NANOG axis', Cancer Research, vol. 78, no. 10, pp. 2638-2653. https://doi.org/10.1158/0008-5472.CAN-17-2325
Oh, Se Jin ; Cho, Hanbyoul ; Kim, Suhyun ; Noh, Kyung Hee ; Song, Kwon Ho ; Lee, Hyo Jung ; Woo, Seon Rang ; Kim, Suyeon ; Choi, Chel Hun ; Chung, Joon Yong ; Hewitt, Stephen M. ; Kim, Jae Hoon ; Baek, Seungki ; Lee, Kyung-Mi ; Yee, Cassian ; Park, Hae Chul ; Kim, Tae Woo. / Targeting cyclin D-CDK4/6 sensitizes immune-refractory cancer by blocking the SCP3–NANOG axis. In: Cancer Research. 2018 ; Vol. 78, No. 10. pp. 2638-2653.
@article{65f7f2c2545a4a1a898771a32b00ebe6,
title = "Targeting cyclin D-CDK4/6 sensitizes immune-refractory cancer by blocking the SCP3–NANOG axis",
abstract = "Immunoediting caused by antitumor immunity drives tumor cells to acquire refractory phenotypes. We demonstrated previously that tumor antigen–specific T cells edit these cells such that they become resistant to CTL killing and enrich NANOGhigh cancer stem cell-like cells. In this study, we show that synaptonemal complex protein 3 (SCP3), a member of the Cor1 family, is overexpressed in immunoedited cells and upregulates NANOG by hyperactivating the cyclin D1–CDK4/6 axis. The SCP3–cyclin D1–CDK4/6 axis was preserved across various types of human cancer and correlated negatively with progression-free survival of cervical cancer patients. Targeting CDK4/6 with the inhibitor palbociclib reversed multiaggressive phenotypes of SCP3high immunoedited tumor cells and led to long-term control of the disease. Collectively, our findings establish a firm molecular link of multiaggressiveness among SCP3, NANOG, cyclin D1, and CDK4/6 and identify CDK4/6 inhibitors as actionable drugs for controlling SCP3high immune-refractory cancer. Significance: These findings reveal cyclin D1-CDK4/6 inhibition as an effective strategy for controlling SCP3high immune-refractroy cancer.",
author = "Oh, {Se Jin} and Hanbyoul Cho and Suhyun Kim and Noh, {Kyung Hee} and Song, {Kwon Ho} and Lee, {Hyo Jung} and Woo, {Seon Rang} and Suyeon Kim and Choi, {Chel Hun} and Chung, {Joon Yong} and Hewitt, {Stephen M.} and Kim, {Jae Hoon} and Seungki Baek and Kyung-Mi Lee and Cassian Yee and Park, {Hae Chul} and Kim, {Tae Woo}",
year = "2018",
month = "5",
day = "15",
doi = "10.1158/0008-5472.CAN-17-2325",
language = "English",
volume = "78",
pages = "2638--2653",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Targeting cyclin D-CDK4/6 sensitizes immune-refractory cancer by blocking the SCP3–NANOG axis

AU - Oh, Se Jin

AU - Cho, Hanbyoul

AU - Kim, Suhyun

AU - Noh, Kyung Hee

AU - Song, Kwon Ho

AU - Lee, Hyo Jung

AU - Woo, Seon Rang

AU - Kim, Suyeon

AU - Choi, Chel Hun

AU - Chung, Joon Yong

AU - Hewitt, Stephen M.

AU - Kim, Jae Hoon

AU - Baek, Seungki

AU - Lee, Kyung-Mi

AU - Yee, Cassian

AU - Park, Hae Chul

AU - Kim, Tae Woo

PY - 2018/5/15

Y1 - 2018/5/15

N2 - Immunoediting caused by antitumor immunity drives tumor cells to acquire refractory phenotypes. We demonstrated previously that tumor antigen–specific T cells edit these cells such that they become resistant to CTL killing and enrich NANOGhigh cancer stem cell-like cells. In this study, we show that synaptonemal complex protein 3 (SCP3), a member of the Cor1 family, is overexpressed in immunoedited cells and upregulates NANOG by hyperactivating the cyclin D1–CDK4/6 axis. The SCP3–cyclin D1–CDK4/6 axis was preserved across various types of human cancer and correlated negatively with progression-free survival of cervical cancer patients. Targeting CDK4/6 with the inhibitor palbociclib reversed multiaggressive phenotypes of SCP3high immunoedited tumor cells and led to long-term control of the disease. Collectively, our findings establish a firm molecular link of multiaggressiveness among SCP3, NANOG, cyclin D1, and CDK4/6 and identify CDK4/6 inhibitors as actionable drugs for controlling SCP3high immune-refractory cancer. Significance: These findings reveal cyclin D1-CDK4/6 inhibition as an effective strategy for controlling SCP3high immune-refractroy cancer.

AB - Immunoediting caused by antitumor immunity drives tumor cells to acquire refractory phenotypes. We demonstrated previously that tumor antigen–specific T cells edit these cells such that they become resistant to CTL killing and enrich NANOGhigh cancer stem cell-like cells. In this study, we show that synaptonemal complex protein 3 (SCP3), a member of the Cor1 family, is overexpressed in immunoedited cells and upregulates NANOG by hyperactivating the cyclin D1–CDK4/6 axis. The SCP3–cyclin D1–CDK4/6 axis was preserved across various types of human cancer and correlated negatively with progression-free survival of cervical cancer patients. Targeting CDK4/6 with the inhibitor palbociclib reversed multiaggressive phenotypes of SCP3high immunoedited tumor cells and led to long-term control of the disease. Collectively, our findings establish a firm molecular link of multiaggressiveness among SCP3, NANOG, cyclin D1, and CDK4/6 and identify CDK4/6 inhibitors as actionable drugs for controlling SCP3high immune-refractory cancer. Significance: These findings reveal cyclin D1-CDK4/6 inhibition as an effective strategy for controlling SCP3high immune-refractroy cancer.

UR - http://www.scopus.com/inward/record.url?scp=85047880240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047880240&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-17-2325

DO - 10.1158/0008-5472.CAN-17-2325

M3 - Article

VL - 78

SP - 2638

EP - 2653

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 10

ER -